Question explored with the scientific record
can a UTI and a infected uterous be a side effect of metformin?
The evidence retrieved does not directly test whether metformin causes urinary tract or uterine infections, but it does show that the infections seen in diabetes trials are linked to a different drug class, not metformin itself.
The studies you received are almost entirely about SGLT-2 inhibitors (dapagliflozin, canagliflozin) and their well-known side effect of raising urinary and genital infection rates [1][2][3][4]. One review explicitly lists "urinary tract infections" and "genital candidiasis" as side effects of SGLT-2 inhibitors, not metformin [6]. In a 102-week trial comparing dapagliflozin plus metformin to placebo plus metformin, the rate of urinary tract infections was nearly identical between groups (6 vs 7 events), and genital infections were low in both [2]. This suggests metformin itself does not drive those infections.
Metformin's most common side effects are gastrointestinal (nausea, diarrhea) [6]. The drug works partly by altering the gut microbiome and improving the intestinal barrier [5][7], which would not be expected to cause a uterine infection. No study in this retrieval reports uterine infection as a metformin side effect. The retrieval did not surface any trial or case series specifically designed to look for uterine infections after metformin use, so the absence of evidence is not proof of safety, but the known mechanism does not point toward that risk.
| Drug Class | Urinary/genital infection risk noted? | Source |
|---|---|---|
| Metformin | No increased risk in these trials | [2][6] |
| SGLT-2 inhibitors (dapagliflozin, etc.) | Yes, consistently reported | [1][3][4][6] |
My call: The evidence does not support a causal link between metformin and either UTI or uterine infection. The infections you are asking about are a known side effect of SGLT-2 inhibitors, a different class of diabetes drug often added to metformin. If you are taking metformin alone, a UTI or uterine infection is unlikely to be caused by it. Confidence: moderate (the retrieval is thin on uterine infection specifically, but the mechanism and comparative trial data are consistent).
Sources used 7
-
The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands
A Dutch health-economic modelling study showing that adding dapagliflozin to metformin plus sulfonylurea is cost-saving and more effective (dominant) than adding DPP-4 inhibitors, mainly due to fewer complications and weight benefits, albeit with more urinary/genital infections.
DOI: 10.1111/dme.14371 -
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
Over 102 weeks, dapagliflozin 10 mg/day added to metformin maintained glycaemic control and produced sustained reductions in weight and total body fat mass in overweight adults with type 2 diabetes, without adverse effects on bone turnover or bone mineral density, and with simil…
DOI: 10.1111/dom.12189 -
Treatment Outcomes of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Co-Transporter-2 Inhibitors in Diabetes Mellitus with Poor Glycemic Control
This prospective, head-to-head comparison in adults with uncontrolled type 2 diabetes on metformin shows that SGLT-2 inhibitors provide greater reductions in fasting and postprandial glucose, HbA1c, and weight loss than DPP-4 inhibitors over 12 weeks, but with higher genital inf…
DOI: 10.3329/jom.v25i2.74306 -
Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
This expert-opinion review compares nine SGLT2 inhibitors in development for type 2 diabetes, detailing their pharmacology (potency and selectivity), preclinical and clinical efficacy (glycemic control, weight, and blood pressure effects), safety profiles (genital and urinary in…
DOI: 10.1517/13543784.2013.774372 -
Metformin exerts glucose-lowering action in high-fat fed mice via attenuating endotoxemia and enhancing insulin signaling
Metformin lowers glucose in high-fat diet–fed mice by reducing gut-derived endotoxemia and enhancing insulin signaling through gut barrier improvement, AMPK activation, and a redox-regulated Nrf2/PTEN axis; antibiotics partially mimic these effects, while exogenous LPS blunts th…
DOI: 10.1038/aps.2016.21 -
Management of type 2 diabetes: now and the future
An educational case-based review of modern type 2 diabetes management, emphasizing metformin as first-line therapy and the cardiovascular/renal benefits of SGLT-2 inhibitors and GLP-1 receptor agonists, with guideline-based, cost-conscious treatment recommendations.
DOI: 10.7861/clinmed.2019-0318 -
Novel mechanism whereby metformin improves glucose homeostasis: TXNIP–GLUT1 axis modulation enhances intestinal glucotonic effects
Metformin improves glucose homeostasis in mice by increasing distal intestinal glucose uptake and excretion (glucotonic effect) via TXNIP downregulation and GLUT1 upregulation, a mechanism independent of AMPK activation.
DOI: 10.1038/s12276-025-01518-w